Researchers: Mitchell B Lee, Benjamin Blue, Michael Muir, Matt Kaeberlein
Targeting aging is the future of twenty-first century preventative medicine. Small molecule interventions that promote healthy longevity are known, but few are well-developed and discovery of novel, robust interventions has stagnated. To accelerate longevity intervention discovery and development, high-throughput systems are needed that can perform unbiased drug screening and directly measure lifespan and healthspan metrics in whole animals. C. elegans is a powerful model system for this type of drug discovery. Combined with automated data capture and analysis technologies, truly high-throughput longevity drug discovery is possible. In this perspective, we propose the “million-molecule challenge”, an effort to quantitatively assess 1,000,000 interventions for longevity within five years. The WormBot-AI, our best-in-class robotics and AI data analysis platform, provides a tool to achieve the million-molecule challenge for pennies per animal tested.
References
- Autophagy in healthy aging and disease.
- Testing the evidence that lifespan-extending compound interventions are conserved across laboratory animal model species.
- Cellular senescence and senolytics: the path to the clinic.
- G protein-coupled receptors that influence lifespan of human and animal models.
- Antiaging diets: Separating fact from fiction.
- C. elegans as an Animal Model to Study the Intersection of DNA Repair, Aging and Neurodegeneration.
- Metabolic changes in aging humans: current evidence and therapeutic strategies.
- mTOR as a central regulator of lifespan and aging.
- Effects of Fisetin, a Plant-Derived Flavonoid, on Response to Oxidative Stress, Aging, and Age-Related Diseases in Caenorhabditis elegans.
- FoxO.
Topic: healthspan (Graph Available)